Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Neoplasms 2Solid Tumors 1Sarcoma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Chondrosarcoma 1Carcinoma, Ovarian Epithelial 1

Interventions

Azacitidine 66venetoclax 21Decitabine 16Cytarabine 12decitabine and cedazuridine drug combination 10AP 1903 reagent 10Cyclophosphamide 7fludarabine 6pevonedistat 5mocetinostat 5ON 01910 5Busulfan 5treosulfan 4sabatolimab 4ruxolitinib 4cedazuridine 4cc-486 4Mycophenolic Acid 4Lenalidomide 4Injections 4plerixafor 3luspatercept 3imetelstat 3glasdegib 3fludarabine phosphate 3Whole-Body Irradiation 3Methotrexate 3GRN163L peptide 3Clofarabine 3CPX-351 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Myelodysplastic Syndromes × birinapant × Clear all
NCT02147873 2016-10-20

Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL

TetraLogic Pharmaceuticals

Phase 2 Terminated
118 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡